Business Description
CureVac NV
NAICS : 541714
SIC : 2833
ISIN : NL0015436031
Share Class Description:
FRA:5CV: Ordinary SharesCompare
Compare
Traded in other countries / regions
CVAC.USA5CV.Germany0A9E.UK1CVAC.ItalyCVAC.AustriaCVAC.Mexico IPO Date
2020-08-14Description
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.1 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.7 | |||||
| Beneish M-Score | 3.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 50.9 | |||||
| 3-Year EBITDA Growth Rate | -29 | |||||
| 3-Year EPS without NRI Growth Rate | -30.6 | |||||
| 3-Year FCF Growth Rate | -50.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 45.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 10.35 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.57 | |||||
| 9-Day RSI | 28.7 | |||||
| 14-Day RSI | 31.28 | |||||
| 6-1 Month Momentum % | -47.85 | |||||
| 12-1 Month Momentum % | -61.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 3.1 | |||||
| Days Inventory | 49.28 | |||||
| Days Sales Outstanding | 55.05 | |||||
| Days Payable | 76.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | -52.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -250.88 | |||||
| Operating Margin % | -720.98 | |||||
| Net Margin % | -704.74 | |||||
| FCF Margin % | -780.83 | |||||
| ROE % | -49.02 | |||||
| ROA % | -34.14 | |||||
| ROIC % | -77.82 | |||||
| ROC (Joel Greenblatt) % | -116.61 | |||||
| ROCE % | -39.69 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.62 | |||||
| PB Ratio | 0.87 | |||||
| Price-to-Tangible-Book | 0.92 | |||||
| EV-to-EBIT | -0.34 | |||||
| EV-to-Forward-EBIT | -0.46 | |||||
| EV-to-EBITDA | -0.36 | |||||
| EV-to-Forward-EBITDA | -0.51 | |||||
| EV-to-Revenue | 2.33 | |||||
| EV-to-Forward-Revenue | 1.69 | |||||
| EV-to-FCF | -0.3 | |||||
| Price-to-Net-Current-Asset-Value | 1.78 | |||||
| Price-to-Net-Cash | 2.31 | |||||
| Earnings Yield (Greenblatt) % | -294.12 | |||||
| FCF Yield % | -63.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CureVac NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 42.88 | ||
| EPS (TTM) (€) | -1.47 | ||
| Beta | 0.72 | ||
| Volatility % | 58.72 | ||
| 14-Day RSI | 31.28 | ||
| 14-Day ATR (€) | 0.158038 | ||
| 20-Day SMA (€) | 2.605 | ||
| 12-1 Month Momentum % | -61.71 | ||
| 52-Week Range (€) | 2.196 - 11.2 | ||
| Shares Outstanding (Mil) | 223.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CureVac NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CureVac NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CureVac NV Frequently Asked Questions
What is CureVac NV(FRA:5CV)'s stock price today?
The current price of FRA:5CV is €2.27. The 52 week high of FRA:5CV is €11.20 and 52 week low is €2.20.
When is next earnings date of CureVac NV(FRA:5CV)?
The next earnings date of CureVac NV(FRA:5CV) is 2024-05-30 Est..
Does CureVac NV(FRA:5CV) pay dividends? If so, how much?
CureVac NV(FRA:5CV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers